Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.32 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Q2 2019 Arbutus Biopharma Corp Earnings Call Transcript

Aug 05, 2019 / 12:45PM GMT
Release Date Price: $1.6 (-1.84%)
Operator

Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Corporation 2019 Second Quarter Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to introduce your host for today's conference, Pam Murphy. You may begin.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Thank you, and good morning. On the call from the Arbutus executives team are Bill Collier, President and Chief Executive Officer; Dave Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with a summary of key corporate and clinical developments and objectives followed by Dave Hastings, who'll provide a review of the company's second quarter financial results. We'll then open up the call for Q&A. Gaston on and Mike will be available to address research and/or clinical development-related questions.

Before we begin, we'd like to remind you that some of the statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot